RET and breast carcinoma: Antibody-drug conjugates targeted to RET or GFRα1, have demonstrated effective and specific killing of breast cancer cells in vitro and in vivo (Nguyen et al., 2015; Bhakta et al., 2017; Bosco et al., 2018).